These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 8215287)
1. Inhibition of Toxoplasma gondii protein synthesis by azithromycin. Blais J; Garneau V; Chamberland S Antimicrob Agents Chemother; 1993 Aug; 37(8):1701-3. PubMed ID: 8215287 [TBL] [Abstract][Full Text] [Related]
2. In vitro effects of four macrolides (roxithromycin, spiramycin, azithromycin [CP-62,993], and A-56268) on Toxoplasma gondii. Chang HR; Pechère JC Antimicrob Agents Chemother; 1988 Apr; 32(4):524-9. PubMed ID: 2837140 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of cytoplasmic and organellar protein synthesis in Toxoplasma gondii. Implications for the target of macrolide antibiotics. Beckers CJ; Roos DS; Donald RG; Luft BJ; Schwab JC; Cao Y; Joiner KA J Clin Invest; 1995 Jan; 95(1):367-76. PubMed ID: 7814637 [TBL] [Abstract][Full Text] [Related]
4. Azithromycin uptake and intracellular accumulation by Toxoplasma gondii-infected macrophages. Blais J; Beauchamp D; Chamberland S J Antimicrob Chemother; 1994 Sep; 34(3):371-82. PubMed ID: 7829411 [TBL] [Abstract][Full Text] [Related]
5. Comparative activity of macrolides against Toxoplasma gondii demonstrating utility of an in vitro microassay. Chamberland S; Kirst HA; Current WL Antimicrob Agents Chemother; 1991 May; 35(5):903-9. PubMed ID: 1854172 [TBL] [Abstract][Full Text] [Related]
6. Effect of clindamycin on intracellular replication, protein synthesis, and infectivity of Toxoplasma gondii. Blais J; Tardif C; Chamberland S Antimicrob Agents Chemother; 1993 Dec; 37(12):2571-7. PubMed ID: 7509143 [TBL] [Abstract][Full Text] [Related]
7. [New pathogens and mode of action of azithromycin: Toxoplasma gondii]. Derouin F Pathol Biol (Paris); 1995 Jun; 43(6):561-4. PubMed ID: 8539083 [TBL] [Abstract][Full Text] [Related]
8. In vivo activity of the macrolide antibiotics azithromycin, roxithromycin and spiramycin against Toxoplasma gondii. Araujo FG; Shepard RM; Remington JS Eur J Clin Microbiol Infect Dis; 1991 Jun; 10(6):519-24. PubMed ID: 1655433 [TBL] [Abstract][Full Text] [Related]
9. Comparison of mutants of Toxoplasma gondii selected for resistance to azithromycin, spiramycin, or clindamycin. Pfefferkorn ER; Borotz SE Antimicrob Agents Chemother; 1994 Jan; 38(1):31-7. PubMed ID: 8141576 [TBL] [Abstract][Full Text] [Related]
10. [In vivo effect of dihydroartemisinin and azithromycin on the ultrastructure of Toxoplasma gondii tachyzoites]. Yin WD; Gao QC; Liu XD; Tang HW Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2009 Aug; 27(4):325-7. PubMed ID: 20066989 [TBL] [Abstract][Full Text] [Related]
11. Activity in vitro against Toxoplasma gondii of azithromycin and clarithromycin alone and with pyrimethamine. Derouin F; Chastang C J Antimicrob Chemother; 1990 Apr; 25(4):708-11. PubMed ID: 2161824 [No Abstract] [Full Text] [Related]
12. Brazilian strains of Toxoplasma gondii are controlled by azithromycin and modulate cytokine production in human placental explants. Franco PS; Gois PSG; de Araújo TE; da Silva RJ; de Freitas Barbosa B; de Oliveira Gomes A; Ietta F; Dos Santos LA; Dos Santos MC; Mineo JR; Ferro EAV J Biomed Sci; 2019 Jan; 26(1):10. PubMed ID: 30665403 [TBL] [Abstract][Full Text] [Related]
13. Azithromycin treatment is able to control the infection by two genotypes of Toxoplasma gondii in human trophoblast BeWo cells. Ribeiro M; Franco PS; Lopes-Maria JB; Angeloni MB; Barbosa BF; Gomes AO; Castro AS; Silva RJD; Oliveira FC; Milian ICB; Martins-Filho OA; Ietta F; Mineo JR; Ferro EAV Exp Parasitol; 2017 Oct; 181():111-118. PubMed ID: 28803905 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of the effect of drugs on the cyst form of Toxoplasma gondii. Huskinson-Mark J; Araujo FG; Remington JS J Infect Dis; 1991 Jul; 164(1):170-1. PubMed ID: 1647421 [TBL] [Abstract][Full Text] [Related]
15. Azithromycin and spiramycin induce anti-inflammatory response in human trophoblastic (BeWo) cells infected by Toxoplasma gondii but are able to control infection. Franco PS; Gomes AO; Barbosa BF; Angeloni MB; Silva NM; Teixeira-Carvalho A; Martins-Filho OA; Silva DA; Mineo JR; Ferro EA Placenta; 2011 Nov; 32(11):838-44. PubMed ID: 21908042 [TBL] [Abstract][Full Text] [Related]
16. Spectrum of activity of azithromycin. Williams JD Eur J Clin Microbiol Infect Dis; 1991 Oct; 10(10):813-20. PubMed ID: 1662624 [TBL] [Abstract][Full Text] [Related]
17. Macrolides with promotive activity of monocyte to macrophage differentiation. Yoshida K; Sunazuka T; Nagai K; Sugawara A; Cho A; Nagamitsu T; Harigaya Y; Otoguro K; Akagawa KS; Omura S J Antibiot (Tokyo); 2005 Jan; 58(1):79-81. PubMed ID: 15813186 [No Abstract] [Full Text] [Related]
18. Licochalcone A: An effective and low-toxicity compound against Toxoplasma gondii in vitro and in vivo. Si H; Xu C; Zhang J; Zhang X; Li B; Zhou X; Zhang J Int J Parasitol Drugs Drug Resist; 2018 Aug; 8(2):238-245. PubMed ID: 29684680 [TBL] [Abstract][Full Text] [Related]
19. Selective labeling of intracellular parasite proteins by using ricin. Gurnett AM; Dulski PM; Darkin-Rattray SJ; Carrington MJ; Schmatz DM Proc Natl Acad Sci U S A; 1995 Mar; 92(6):2388-92. PubMed ID: 7892277 [TBL] [Abstract][Full Text] [Related]
20. In vitro evaluation of the activities of azithromycin alone and combined with pyrimethamine against Toxoplasma gondii. Cantin L; Chamberland S Antimicrob Agents Chemother; 1993 Sep; 37(9):1993-6. PubMed ID: 8239619 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]